Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis in convenient administration forms.
At Cyxone we consider the unmet need from an alternative perspective. The company’s vision is to develop therapeutics that markedly improve the quality of life for patients based on recent understandings of the disease mechanism. Our drugs are designed not only to be efficacious, but also more convenient for patients to take, have fewer and milder side-effects than existing treatments, and well-suited for long-term treatments. By providing this we will offer patients the option of taking control of their disease, and thereby their lives.
Cyxone was founded in 2015 and its stock is traded on Nasdaq First North Growth Market since 2016. The company currently has two unique clinical-phase projects, both developing towards important and potentially value-creating milestones.
The development portfolio comprises Rabeximod, which is a clinical Phase 2 compound for rheumatoid arthritis (RA). Separately, Cyxone has performed a Phase 2 study to investigate the benefits of Rabeximod as a treatment for Covid-19 to combat virally induced acute respiratory conditions and prevent progression to virally induced acute respiratory distress syndrome (ARDS). The company is also developing T20K as a new treatment for multiple sclerosis (MS), based on encouraging preclinical results and a successful but limited phase 1 infusion study. More preclinical work is needed since infusion is not Cyxone’s intended administration mode.
The company is well positioned to become an important player in the commercially attractive field of disorders of the immune system, aiming at improving patients’ quality of life, lowering health care costs as well as creating substantial value for its shareholders.